Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Empagliflozin vs JARDIANCE in Healthy Thai Volunteers
NCT06337409Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Primary endpoint: Maximum Plasma Concentration. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06337409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337409.